A.G. Rhodes openly sharing the path to the future of long-term care via its $37.5M ‘household’ renovation
By
Josh Henreckson
Jun 20, 2024
After nearly a decade of planning, fundraising and a $37.5 million construction and renovation project, Atlanta-based provider AG Rhodes officially opened its new 72-bed “household-model” building...
Master plan on aging fails to ensure ‘robust’ long-term care continuum that includes senior living,...
By
Kimberly Bonvissuto
Jun 10, 2024
Pennsylvania’s master plan on aging, although well-intended, focuses most of its attention on home care and community services and falls short of ensuring a “robust” long-term care continuum for...
Care provider to pay $14.9M over false claims involving assisted living communities
By
Kimberly Bonvissuto
Jun 10, 2024
A chronic disease management provider will have to shell out $14.9 million over allegations related to false claims involving assisted living communities, memory care communities and group homes.
The owners and operators of multiple New York adult care facilities and assisted living programs are facing a discrimination lawsuit for reportedly turning away prospective residents who use wheelchairs.
Patient–primary care provider language concordance tied to better outcomes
Jul 02, 2024
The findings were seen for non-English and non-French speakers living in Canada.
Self-administered gerocognitive exam improves detection of cognitive issues in primary care
Jul 02, 2024
Detection rates appear to increase during nonacute office visits.
Substituting lower-wage staff for registered nurses tied to worse outcomes
Jun 25, 2024
Harms include avoidable patient deaths, readmissions, longer lengths of stay, excess Medicare costs and forgone cost savings.
Low incidence of delayed intracranial hemorrhage seen in seniors after head injury
Jul 03, 2024
No differences were seen in rates of delayed intracranial hemorrhage between those who have been versus those who have not been prescribed anticoagulants.
FDA approves new drug to treat Alzheimer’s
Jul 02, 2024
In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early stages of the memory-robbing disease. But it also carried significant safety risks, including...
Few with type 2 diabetes receive guideline-recommended CKD screening
Jul 01, 2024
24.9 percent received creatinine and UACR screening; Hispanic ethnicity associated with lack of screening